Committee Insights | 3.1.22 | Cannabis and COVID-19 – What We Know and What We Don’t
Marijuana Laws, Regulations, & Politics March 22, 2022 MJ Shareholders 0
[embedded content]
In this edition of our NCIA Committee Insights series originally aired on Tuesday, March 1, 2022 members of NCIA’s Scientific Advisory Committee convened a panel of leading clinical, regulatory and cannabis technology experts to lead a very timely discussion surrounding cannabis and COVID-19.
This webinar gave an overview of the effects of COVID-19 on the body with a discussion on the research related to cannabis based treatments.
Presentation Slide Deck: https://bit.ly/3tjbcvi
Learning Objectives:
• Learn about COVID-19 and how it infects the mammalian body’s organ systems.
• Discuss the endocannabinoid systems role in the immune response and how research supports its role in COVID-19.
• Outline implications of cannabinoid treatments based on available research including the most recent acidic cannabinoid study that has been all over the media.
• Identify areas of interest for future research.
Speakers:
Dr. Paloma Lehfeldt, MD, MA
Senior Director of Clinical Science and Partnerships
Goodness Growth Holdings
Lucy Postolov
Owner and President
Cannapy Health LLC / Postolova Acupuncture Group, Inc.
Bryant Godfrey
Partner
Foley Hoag
Jim Makoso
Director / CEO
Lucid Lab Group / Flowe Technology
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
No comments so far.
Be first to leave comment below.